Delving into the Latest Updates on REGN-6490 with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms-

Target

IL-36R

Action

inhibitors

Mechanism

IL-36R inhibitors(Interleukin-36 receptor inhibitors)

Therapeutic Areas-

Active Indication-

Inactive Indication-

Originator Organization

Regeneron Pharmaceuticals, Inc.

Active Organization-

Inactive Organization

Regeneron Pharmaceuticals, Inc.

License Organization-

Drug Highest PhaseDiscontinuedPhase 1

First Approval Date-

Regulation-

Login to view timeline

The primary objective of the study is to evaluate the safety and tolerability of single ascending intravenous (IV) and subcutaneous (SC) doses of REGN6490 in healthy adult participants
The secondary objectives of the study are to:
Characterize the pharmacokinetic (PK) profile of single IV and SC doses of REGN6490 in healthy adult participants
Assess immunogenicity of REGN6490 in healthy adult participants dosed with a single IV or SC dose of REGN6490

Start Date19 Nov 2020

Sponsor / Collaborator

Regeneron Pharmaceuticals, Inc.

NCT04616105

/ TerminatedPhase 1

A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of REGN6490 in Healthy Japanese Volunteers

The primary objective of the study is to evaluate the safety and tolerability of 3 single ascending subcutaneous (SC) doses and 1 single intravenous (IV) dose of REGN6490 in healthy first-generation Japanese adult participants
The secondary objectives of the study are:
To characterize the pharmacokinetic (PK) profile of single SC and IV doses of REGN6490 in healthy first-generation Japanese adult participants
Assess immunogenicity of REGN6490 in healthy first-generation Japanese adult participants dosed with a single IV or SC dose of REGN6490

Start Date18 Nov 2020

Sponsor / Collaborator

Regeneron Pharmaceuticals, Inc.

100 Clinical Results associated with REGN-6490

Login to view more data

100 Translational Medicine associated with REGN-6490

Login to view more data

100 Patents (Medical) associated with REGN-6490

Login to view more data

100 Deals associated with REGN-6490

Login to view more data

R&D Status

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data